Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RMC-6291 in Advanced KRASG12C Mutant Solid Tumors
NCT05462717Phase 1Active, not recruiting
- Sponsor
- Revolution Medicines
- Start
- Sep 2022
- Primary completion
- Mar 2027
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 1, open-label, single-arm trial of elironrasib in solid tumor, non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and 1 more, sponsored by Revolution Medicines. Primary endpoints: Adverse Events at 3 years and Dose Limiting Toxicities at 21 days. Started Sep 2022; status: active, not recruiting.
02
Drugs
elironrasib
03
Conditions
solid tumornon-small cell lung cancer (NSCLC)colorectal cancer (CRC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05462717.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05462717.